Химиотерапия резистентных форм хронического лимфолейкоза с учетом результатов чувствительности опухолевых клеток in vitro
Первым этапом нашего исследования было проведение скрининга чувствительности опухолевых клеток к различным ХП в культуре МТТ. Клетки опухоли считались чувствительными, если количество погибших клеток в культуре составляло не менее 50% (LD50) со средней из пяти используемых концентраций препарата, которая рассчитывалась с помощью теоретической плазменной концентрации (ТПК). В литературе… Читать ещё >
Содержание
- Список использованных сокращений
Глава 1. Резистентность к химиопрепаратам и пути ее преодоления. Обзор литературы.
1.1. Транспорт и метаболизм в развитии лекарственной резистентности.
1.2. Лекарственная резистентность, связанная с активностью то-поизомераз.
1.3. Лекарственная резистентность, связанная с нарушениями апоптоза.
1.4. Методы исследования лекарственной чувствительности в культуре и их клиническое значение: DiSK-метод и МТТ-метод.
1.5. Аддитивный эффект противоопухолевых препаратов, выявленный в МТТ культуре.
1.6. Исследование in vitro как модель для изучения новых или известных препаратов, которые ранее не использовались в лечении хронического лимфолейкоза.
Глава 2. Методы исследования.
2.1. Клиническая характеристика больных.
2.2.0ценка эффективности химиотерапии.
2.3.0пределение чувствительности опухолевых лимфоцитов к противоопухолевым препаратам методом МТТ-анализа.
2.4. Определение иммунологического иммунофенотипа на опухолевых клетках периферической крови методом проточной цито-флуометрии.
2.5.Статистическая обработка данных.
Глава 3. Химиотерапия алкераном рефрактерных больных ХЛЛ с учетом чувствительности в МТТ- тесте.
3.1. Скрининг чувствительности опухолевых клеток к различным химиопрепаратам в культуре.
3.2. Химиотерапия алкераном (сарколизином) рефрактерных больных ХЛЛ.
Глава 4. Химиотерапия рефрактерных больных ХЛЛ флюдарабином с учетом чувствительности опухолевых клеток в МТТ-тесте.
Список литературы
- Барышников А.Ю., Кадагидзе З. Г., Махонова Л. А., Тупицин Н. Н. Иммунологический фенотип лейкозной клетки.1. Москва: Медицина, 1989.2. Барышников А.Ю.
- Программированная клеточная смерть (апоптоз).
- Клиническая онкогематология: руководство для врачей, М.: Медицина, 2001, с. 36−42.
- Голенков А.К., Абдул Латиф Шахер, Митирев Г.Ю.
- Иммунологический фенотип и клиническое течение неходжкинских лимфом. Гематология и трансфузиология, 1998, № 1, с. 41−44.4. Голенков А.К.
- Лечение сарколизином множественной миеломы и хронического лимфолейкоза. Российский Биотерапевтический журнал, 2002, № 2, с. 36−39.5. Переводчикова Н.И.
- Химиотерапия опухолевых заболеваний, М, 2000, с. 359, с.364−371.6. Ставровская А.А.
- Резистентность больных гемобластозами к лекарственной терапии: молекулярные механизмы и проблемы преодоления множественной лекарственной устойчивости. Клиническая онкогематология: руководство для врачей, М.: Медицина, 2001, с. 43−51.7. Фрешни Р.
- Культура животных клеток. Методы. Москва, «Мир», 1989, стр. 264−265.8. Шишкин Ю.В.
- CD95 опосредованный апоптоз в лейкозных и нормальных кроветворных клетках. Дис. докт. мед. наук, М.2000.9. Balducci D.M.
- Arsenic trioxide (As203) down regulates procoagulant activities of human acute promyelocytic and breast cancer cells.
- The Hematol. Journ., 2003, V.4, S.2, p. 268.
- Beck J., Neithammer D., Gekeler V.
- High mdrl and mrp, but low topoisomerase II a gene expression in B-cell chronic lymphocytic leukemias. T
- Cancer Letters, 1994, V. 86, p. 135−142.
- Beck J., Neithammer D., Gekeler V.
- MDR1, MRP, topoisomerase II a/p, and cyclin A gene expression in acute and chronic lymphocytic leukemias.1.ukemia, 1996, V. 10 (Suppl. 3), p.839−845.
- Bellosillo В., Colomer D., Pons G., Gil J.
- Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells.
- Brit. j. of Haematol., 1998, 100, p. 142−146.
- Bellosillo В., Villamor N., Colomer D., Pons G., Montserrat E., Gil J.1. vitro Evaluation of Fludarabine in Combination with Cyclophosphamide and/or Mitoxantrone in B-Cell Chronic Lymphocytic Leukemia. Blood, 1999, V.94, p. 2836−2843.
- Benet I., Terol M.J., Sarsotti E., Marugan I., Martinez-Climent J.A., Ruiz M.A., Carral A., Montagud M., de Miguel A., Ortuno F., Garcia R., Garcia-Conde J.
- A simple Clinicobiological Prognostic Score Identifies a Group of Patients with B-CLL at Binet Stage A with Poor Prognosis.
- Blood, 2002, V.100, Nol 1, part 2, p. 351b.
- Berenson J., Yang H., Vescio R., Swift R.
- Preliminary findings in a phase II study of trisenox (arsenic trioxide) doses twice weekly in patients with advanced multiple myeloma The Hematology. Journ. 2003, V4, S2,p 163
- Bergmann M.B., Schmitt В., Wendtner C.M., Emmerich В., Herold M., Wilhelm M., Boning L., Hallek M.
- Severe hematological and non-hematological toxicity but good efficacy of bendamustine (B) in pretreated patients with CLL-results of a phase I study of the german CLLstudy group (GCLLSG).
- The Hematology Journal, 2002, V. 3, S. l, p. 249.
- Berrebi A., Schvidel L., Braeshter A., Levine N., Valinsky L.
- Statistically Significant Correlation between T-Associated Antigen Markers, as Expressed by the Ratio CD5-CD3/CD3, and Disease Severity in B-CLL. Blood, 2002, V.100, Noll, part 2, p. 350b.
- Binet J.L., Dighiero G., CatovskyD., Hansen M., Jaksic В., Kimby E., Montserrat E., Richards S., WiernikP.
- Collaborative meta-analysis of randomised trials in chronic lymphocytic leukaemia (CLL). British Journal of Haematol., 1998, V.102,No l, p.277.
- Blonski J.Z., Najder M., Kasznicki M., Robac T.1.munological profile in chronic lymphocytic leukemia-treated with cladribine or chlorambucil
- The Hematology Journal, 2002, V. 3, S. l, p. 246.
- Bonati A., TabilioA., Loloco F., Pelicci P.G., Lunghi P.
- Therapeutic targeting of the MEK-ERK pathway enhances arsenic trioxide-mediated apoptosis in acute promyelocytic leukemia. The Hematol. Journ., 2003, V4, S. 2, p. 67.
- Bosanquet A.G., Brito-Babupulle F., Sykes H.V., Thornton P.D.
- Ex Vivo Efficacy of the Nitrosoureas Carmustine (BCNU) and Lomustine (CCNU) in Chronic Lymphocytic Leukemia (CLL) and Clinical Responses in Heavily Pretreated Patients. Blood, 2002, V.100,Noll, part 2, p. 363b.
- Bosanquet A.G., Copplestone J.A., Jonson S., Smith A.G., Povey S J., Orchard J., Oscier D.G.
- Response to cladribine in previosly treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay. Brit.j. Of Haematol., 1999, 106, p.474−476.
- Bosanquet A.G., Johnson S.A., Richards S.M. Do not treat all CLL patients with fludarabine? British Journal of Haematol., 1998, V.102,No l, p. l90.
- Bosanquet A.G., Jonson S., Richards S.M.
- Prognosis for fludarabin therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay. Brit.j. of Haematol., 1999, 106, 71−77.
- Bosanquet A.G., Stephen A.J., Richards S.M.
- High mortality of DiSC assay- resistant CLL patients treated with fludarabine. Brit.j. OfHeamatol., V. 101, S. l, 1998, p.24.
- Bowen A.L., Bosanquet A.G., Catovsky D., Matutes E.
- P53 deletion and fludarabine-resistance in chronic lymphocytic leukaemia. British Journal of Haematology, 1999, V. 105, S. 1, p.85.
- Bowen A.L., Dearden C.E., Matutes E., Catovsky D. Fludarabine-combination chemotherapy in chronic lymphocytic leukaemia. British Journal of Haematology, 1999, V. 105, S. l, p.85.
- Bramson J., McQuillan A., Panasci L.
- DNA repair enzyme expression in chronic lymphocytic leukemia vis-a-vis nitrogen mustard drug resistance.
- Cancer Lett., 1995, V.90, p.139−148.
- Bruno A., Del Poeta G. Del Principe, Maurillo L.
- High apoptotic index by propidium iodide identifies patients with poor prognosis in B-cell chronic lymphocitic leukemia Hematology Journ. 2003, V4, S 52, p. 187.
- Bueso-Ramos C.E., Ferrajoli A, Keating M. J., Estrov Z.
- Aberrant Cytokinesis, Proliferation, and Apoptosis of B-Cell Chronic Lymphocytic Leukemia Cells.
- Blood, 2002, V.100, Noll, part 2, p. 350b.
- Cabrelle A., Trentin L., Dal-Zilio В., Maschio N., Baesso I., Facco M., Trevisan Т., Binotto G., Agostini C., Zambello R., Semenzato G.
- Apoptotic Effect of Dexamethasone and Cyclosporin A in Malignant Cells of B-CLL Patients Blood, 2002, V.100, Noll, part 2, p. 354b.
- Callera F., Garcia A.B., Falcao R.P.
- Fas-mediated apoptosis with normal expression of bcl-2 and p53 in lymphocytes from aplastic anaemia.
- Brit. j. of Haematol., 1998, 100, p.698−703.
- Carson D.A., Ribeiro J.M. Apoptosis and disease.1.ncet, 1993, V. 341, N 8855, p. 1251−1254.
- Catovsky D., Hamblin Т., Richards S.
- Preliminary results of the UK Medical Research Counsil trial in chronic lymphocytic leukaemia -CLL3.
- British Journal of Haematol., 1998, V.102,No l, p.278.35. Cheson B.D.
- Chronic Lymphoid Leukaemias.
- Clinical Oncology.- New York, 1995.- p. 1999−2022.
- Cheson B.D., Bennet J.M., Rai K.R., Grever M.R., Kay N.E.
- Guidelines for clinical protocols for Chronik Lymphocytic Leukemia: recommendations of the National Cancer Institute sponsored Working Group. American Journal of Haematology 29:152−163(1988).
- Cheson O’Brien S., Gicho A., Keating M.
- Advances in the Biology and Treatment of B-Cell Chronic Lymphocytic Leukaemia. Blood.-V. 85, No 2, 1995, Chesonp. 307−318.
- Chia P., Scielzo C., Guida G., Strola G., Granziero L., Caligaris-Cappio F.
- The Functional Response to CD40 Ligation Reveals Two Subsets of CLL Patients with Different Clinical Prognosis. Blood, 2002, V.100, Nol 1, part 2, p. 356b.
- Chiang A.Y., Liu L.F., Costin D., Wall M.E., Wani M.C., Silber R., Potmesil M.10,11-Methylenedioxy derivates: Biochemistry of second generation camptothecine analogs. Am. Assoc. Cancer Res, 1993, V. 34, p.327.
- Christiansen I., Sundstrom Ch., Totterman Th.
- Elevated serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) closely reflect tumour burden in chronic B-lymphocytic leukaemia. Brit. j. of Haematol., 1998, 103, p. 1129−1137.
- Clodi K., Asgary Z., Zhao Sh., Kliche K., Cabanillas F., AndreefFM., Younes A. Coexpression of CD40 and CD40 Iigand in B-cell lymphoma cells.
- Brit. j. of Haematol., 1998, 103, p. 270−275.
- Clodi K., Snell V., Zhao Sh., Cabanillas F., AndreefFM., Younes A. Unbalanced expression of Fas and CD40 in mantle cell lymphoma. Brit. j. of Haematol., 1998, 103, p. 217−219.
- Collins R.J., Verschuer L.A., Harmon B.V.
- Spontaneous cell death (apoptosis) of B-chronic lymphocytic leukemia cells following their culture in vitro.
- Brit. J. Haematol.- 1989.-V.71, № 3, p.345−350.
- Consoli U., El-Taunsi I., Sandoval A., Snell V., Klein H., Brown W., Robinson J.R., Di-Raimondo F., Plunkett W., ChesonAndreeff M. Cheson
- Differential Induction of Apoptosis by Fludarabine Monophosphate in Leukemic В and Normal T Cells in Chronic Lymphocytic Leukaemia. Blood, -V.91,-No5, 1998, p. 1742−1748.
- Consoli U., Priebe W., Ling Y., Mahadevia R., GriffinM., Zhao Sh., Perez-Soler R., An-dreeffM.
- The Novel Anthracycline Annamycin Is Not Affected by P-Glycorotein Related Multidrug Resistance: Comparison With Idarubicin and Doxorubicin in HL-60 Leukemia Cell Lines. Blood, V.88, No 2, 1996, p. 633−644.
- Conte G.F., Aravena P.C., Fardella P.D., Alfaro J.I., Araos D.M., Flores C.A., Gonzalez N.A.
- Fludarabine as Therapy in Chronic Lymphocytic Leukemia (CLL) in Patients over 70 Years. Blood, 2002, V. 100, No 11, part 2, p. 363b.
- Costin D., Potmesil M., Morse L., Mani M., Canellakis Z.N., Silber R. Sensitivity of chronic lymphocytic leukemia B-lymphocytes to camptothecin analogues. The 4th Conference on DNATopoisomerases in Therapy. New York, NY, 1992, p. 53.
- Curt G.A., ClendeminnN.I., Chabner В .A. Drug resistance in cancer.
- Cancer Treat Rep 68: 87−99, 1984.
- Damiani D., Michieli M., Grimaz S., Ermacora A., Masolini P., Baccarani M. Absence of PGP expression and high intracellular daunorubicin accumulation distinguish AHLL with good prognosis.
- British Journal of Haematol., 1998, V.102,No l, p.331.
- De Vries J.F., Barge R.M.Y., Willemze R., Falkenburg J.H.F.
- Cytarabine-mediated killing of B-CLL cells does not require cell proliferation and DNA incorporation.
- The Hematol. Journ. 2003, V.4, S 2, p. 189.
- Dedoussis G.Y.Z., Menounos P., Kyrtsonis M.-C., Karameris A., Maniatis A. Endogenous produced interleukin-6 protects K562 cells from cisplatin mediated cytotoxicity. British Journal of Haematol., 1998, V. 102, No l, p.330.
- The Hematology Journal, 2002, V. 3, S. l, p. 357.
- Del Poeta G., Del Principe M.I., Maurillo L., Venditti A., Buccisano F., Tamburini A., Suppo G., Suppo G., Mazzone C., Mazzone C., Tendas A., Marini R., Irno Consalvo M., Masi M., Amadori S.
- Sequental fludarabine and rituxmab therapy improves outcome in B-chronic lymphocytic leukemia (B-CLL).
- The Hematology Journal, 2002, V. 3, S. l, p. 247.54. den Boer M., Holleman A., Kazemier K.M., Janka-Schaub G., Pieters R.
- Chronic lymphocytic leukemia treatment. Hematology and Cell Therapy, 1997, V. 39, p. S31-S40.
- Dighiero G., Maloun K., Dsabiens В., Cazin В., Navarro M., Leblay R., Leporrier M., Jaubert J., Lepeu G., Dreyfus В., Turpin F.-L., Tertian G., Bichoffe A., Binet J.-L., Travade P.
- Early use of clorambucil is unable to influence survival in stage A chronic lymphocytic leukaemia (CLL) patients. Long term results from two randomized trials of the french copera-tive group in CLL.
- British Journal of Haematol., 1998, V.102,No l, p.278.
- Dohner H., Stilgenbaurer S., Krober A., Dohner K., Leupolt E., Bentz M., Ho A.D., Ben-ner A., Lichter P.
- Chromosome aberrations identify prognostic subgroups of B-cell chronic lymphocytic leukaemia.1. Blood, 1998,92,p.429a.
- Dvorakova K., Payne C.M., Landowski T.U., Tome M.E.1.exon activates an intrinsic apoptosis pathway in RPMI 8226 myeloma cells. Anti-Cancer Drugs, 2002, 13, p. 1031−1042.
- El Roubi S., Thomas A., CostinCheson D., Rosenberg C.R., Potmesil M., Silber R., New-comb E.
- Р53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood, 1993, V. l 1,3452.
- Fagerstrom S., OlssonB., Jarnas M., Jacobsson S., SwolinВ., Carlsson В., Carlsson L., Wadenvik H.
- Gene expression profile in indolent compared to aggressive chronic lymphocytic leukaemia. The Hematology Journal, 2002, V. 3, S. l, p. 247.
- Fang W., Nath K.A., Mackey M.F., NoeUe R.J., Mue D.L., Behrens T.W.
- CD40 inhibits В cell apoptosis by upregulating Bcl-XL expression and blocking oxidant accumulation.
- American journal of Physiology, 1997, 272, C950-C956.
- Faria J.R., Faria R.M.D., Yamamoto M., Kerbauy J., Oliveira J.S.R. Expression of Apoptosis-Modulating Proteins in Chronic Lymphocytic Leukemia. Blood, 2002, V.100, Noll, part 2, p. 352b.
- Fingerle-Rowson G., Busch R., Schmitt В., Wendtner C., Bergmann M., Kuhn- Hallek I., Vehling-Kaiser U., Jager U., Echart M., Nerl Ch., Emmerich В., Hallek M.
- Evaluation of Clinical Prognostic Factors for Progression-Free Survival in Patients with B-CLL in Stage Binet A: An Interim Report from the CLL1 Protocol of the German CLL Study Group (GCLLSG)
- Blood, 2002, V.100, Noll, part 2, p. 358b.
- Foa R., Vischia F., Pini M., Lauria F., GuariniA.
- Use of the MTT chemosensitivity assay in B-cell chronic lymphocytic leukemia. Leuk. Lymphoma, 1991, S. 5, V.3, p. 71.
- Foon K.A., Rai K.R., Gale R.P.
- Chronic lymphocytic leukemia: new insights into biology and therapy. Ann. Intrn. Med., 1990, V. 113, 529−539.
- Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E., Magrath I.T., Knowles D.M., Della-Favera R.
- P53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Cheson Proc. Nati Acad.Sci. USA, 1991, 88, p.5413.
- Gamberale R., Gefiner J.R., Trevani A., Chernavsky A., Scolnik M., Arrosagaray G., Sarmiento M., Giordano M.1.mune complexes inhibit apoptosis of chronic lymphocytic leukaemia В cells. Brit. j. of Haematol., 1999, 107, p.870−876.
- Garnache F., Billot M., Poulet, Bulabois В., Saas P., Brion A., Darodes de Tailly P. Relevance of the CD38 expression with the diagnosis of de novo chronic lymphocytic leukaemia.
- The Hematology Journal, 2002, V. 3, S. l, p. 242.
- Gengenbacher D.M., Romanakis K., Knipper R., Schmetzer В., Bender M., Fauser A.A. Impact of cell cycle analisis and drug resistance for monitoring and followup of gematologic malignancies.
- British Journal of Haematol., 1998, V.102,No l, p.331.
- GerbilN. M. :Tonks A., Burnett A.K.
- A Comparison of the effects of arsenic trioxide on Apoptosis induction and inhibition of proliferation between acute promyelocytic leukemia and multiple myeloma cell lines. The Hematol. Journal 2003, V.4. S, 2, p. 34.
- Ghia P., Guida G., Stella S., Scielzo C., Gottardi D., Geuna M., Strola G., Caligaris-Cap-pio F.
- Bimodal expression of CD38 defines a distinct subset of chronic lymphocytic leukemia patients at risk of disease progression. The Hematology Journal, 2002, V. 3, S. l, p. 357.
- Ginaldi L., D’Ostilio A., De Martinis M., Loreto M.F., Marini L., Martorelli V., Quaglin-oD.
- The value of immunophenotypic analyses in the characterization of B-CLL. British Journal of Haematology, 1999, V. 105, S. 1, p.83.
- Glass В., Dingeldein S., Rave-Frank M., Hasenkamp J.
- Radiation and Rituximab have additive cytotoxic and proapoptotic effects on B-cell lymphoa cell lines in vitro.
- The Hematol. J., 2003, V.4, S.2, p. 108.
- Golay J., Manganini M., Facchinetti V., Broady R.1.-2 increases the susceptibility of freshly isolated neoplastoc B-cells to Rituximab-mediated antibody-dependent cellular cytotoxcity in vitro. The Hematol. J., 2003, V.4, S.2, p. 94.
- Gonzalez-Garcia C., Montes-Ares O., Majado M.J., Montes-Casado M., Marin L.A., TamayoM., Moya-Quiles R.
- Chronic Lymphocytic Leukemia: HLA Class I and CD23 Expression. Blood, 2002, V. l00,Noll, part 2, p. 349b.
- Griesinger F., Kintrup Т., Truemper L.H., Brittinger G., Simon H.
- Retrospective Analysis of CD38 Expression in B-CLL with a Maximum Follow-Up Period of 16.7 Years: Incidence and Prognostic Significance. Blood, 2002, V. l00, No 11, part 2, p. 358b.
- Grudeva J., Nenova I., KarnolskyL, MatevaN. CLL Significance of Some Prognostic Factors. Blood, 2002, V. l00, Noll, part 2, p. 350b.
- Guenther A., Baum W., Burger R., Bakker F., Faller G. Zolendronic acid inhibits myeloma growth in vitro and in vivo. The Hematol.Journ. 2003, V4, S 2, p. 257−258.
- Guilhaume M.-N., Tabuteau S., Royer В., Qachouh M., Garidi R., Fernandes J., Las-soued K., Desablens B.
- Prognostic Value of Seric Immunoglobulin Levels in B-CLL. Analysis on 272 Patients. Blood, 2002, V.100, Noll, part 2, p. 359b.
- Haarman E.G., Kaspers G.J.L., Pieters R., Rottier M.M.A., Veerman A.J.P. Comparative In Vitro Citotoxicity of Prednisolone, Methylprednisolone, Dexamethasone and Cortivazol in Childhood.
- Blood, 2002, V. l00, Noll, part 2, p. 225b.
- Hanada M., Delia D., Aiello A., Stadtmauer E., Reed J.C.
- Bcl-2ne hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood, V.82, 1993, p.1820−1828.
- Hanson J.A., Bentley D.P., Bean E.A., Nute S.P., Moore J.L.1. vitro chemosensitivity testing in chronic lymphocytic leukaemia patients. Leuk. Res., 1991, V. l5, p. 565.
- Heredia Z.D., Mann K.K., Schipper H.M., Waxman ., Miller W.H. Effect of Methylation on the Arsenic-Mediated Apoptosis in APL Cells. Blood, 2002, V.100, Nol 1, part 2, p. 222b.
- Hilgenfeld E., KnaufW.U., ThielE.
- Cytotoxity of fludarabine in vitro cannot predict clinical outcome in patients with advanced stage B-cell chronic lymphocytic leukemia (B-CLL). Leukemia, 1995, V.9, p.541−546.
- Hilgenfeld E., KnaufW.U., Thiel E.1. vitro and in vivo cytotoxicity of fludarabine in patients with advanced stage B-cell chronic lymphocytic leukemia (B-CLL).
- Drug Resistance in Leukemia and Lymphoma II edited by R. Pieters, G.J.L. Kaspers and A.J.P. Veerman, Netherlands, Harwood, 1997, p. 245−253.
- Hilgenfeld E., KnaufW.U., Thiel E.1. vitro and in vivo cytotoxitity of fludarabine in patients with advanced stage B-cell chronic lymphocytic leukemia (B-CLL)
- Drug resistance in leukemia and lymphoma II. Edited by R. Pieters, G.J.L. Kaspers and A.J.P.Veerman, 1997, Amsterdam, p. 245−253.
- Hongo Т., Yajima Sh., Sakurai M., Horikoshi Y., Hanada R.1. vitro Drug Sensitivity Testing Can Predict Induction Failure and Early Relapse of Childhood Acute Lymphoblastic Leukemia. Blood, V.89, No8, 1997, p.2959−2965.
- Huang P., Robertson L.E., Wright S., PluncettS.
- High-molecular weight DNA fragmentation: a critical event in nucleoside analog-inducedapoptosis in leukemia cells.
- Clin. Cancer Res., 1995, V. l, N 9, p. 1005−1013.
- Huh Y.O., Lee J.N., Lerner S., Wierda W.G., Swen C., Keating M.J. T-Cell Subsets in В Cell Chronic Lymphocytic Leukemia.
- Blood, 2002, V.100, Noll, part 2, p. 358b.
- Imamura J., Miyoshi I., Koeffler H.P. P53 in hematological malignancies. Blood, 1994, V. 84, n 8, p. 2412−2421.
- Introna M., Gramigna R., Facchinetti V., Broady R., Borleri G.M., Barbui Т., Rambaldi A., Golay J.
- Susceptibility of freshly isolated B-NHL and B-CLL to rituximab induced cellular and complement lysis in vitro.
- The Hematology Journal, 2002, V. 3, S. l, p. 248.
- Ito K., Kizaki M., Nakazato Т., Ikeda Y.
- New insights of caffeine as ah inducer of G2/M phase cell cycle arrest via a novel p53-depen-dent pathway in NB4 promyelocytic leukemia cells. The Hematol. Journ., 2003, V4, S.2, p. 262.
- Jabbar Sh. А. В., Rassam S. M. B.
- T-Cells Isolated from Chronic Lymphocytic Leukaemia (CLL) Patients Can Be Expanded In Vitro Using CD3/CD28 Costimulation and Feeder Cells- Evidence for Apoptotic humoral Factors Affecting In Vitro Expansion Blood, 2002, V. 100, Noll, part 2, p. 359b.
- Jabbar Sh.A.B., Rassam S.M.B.
- B-Cells Isolated from Chronic Lymphocytic Leukaemia Patients Survive and Expand In Vitro When Culttured with Autologous Sera: Strong Correlation of Growth Pattern with Clinical Status of Patients.
- Blood, 2002, V.100, Noll, part 2, p. 359b.
- Jajeh A., Ali S., Abboud W., Hadad L., Zalzaleh G.
- Pentostatin with an Alkylating Agents in Refractory or Relapsed Chronic Lymphocytic Leukemia.
- Blood, 2002, V.100, Nol 1, part 2, p. 366b.
- Jakab K., Szakacs G., Nahajevszky S., Hollo Zc., Sarkadi B.
- Quantitative determination of multidrug resistance expression and function in haematological malignancies.
- British Journal of Haematol., 1998, V.102,No l, p.331.
- JamroziakK., SmolewskiP., RobeyR.W., CebulaB., Balcerczak E., MirowskiM., Szmigielska-Kaplon A., Bates S.A., Robak T.
- Activity of Breast Cancer Resistance Protein (BCR/ABCG2) in B-Cell Chronic Lymphocytic Leukemia (B-CLL)
- Blood, 2002, V.100, Noll, part 2, p. 356b.
- Johnson S., Smith A.G., Loffler H.
- Complications in the treatment of CLL with purine analogues. Hematology and Cell Therapy, 1997, V. 39, p. S41-S44.
- Juliusson G., Elmhorn-Rosemberg A., Liliemark J.
- Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N. Engl.j. Med., 1992, V. 327, p.1056−61.
- Kaspers G.I., Pieters R., Hahlen K., Veerman A.I.1. vitro drug resistance is related to long-term clinical outcome in childhood acute lymphoblastic leukemia.
- Proc.Annu Meet. Am. Soc. Clin. Oncol., 1991, V. 10, p. A800.
- Kaspers G.I., Pieters R., van Zantwijk C.H.1. vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukemic cells from bone marrow and peripheral blood Brit. j. Cancer, 1991, V. 64, p. 469−4.
- Kerr J.F.R., Winterford C.M., Harmon B.V. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994.- V.73, .p.2013−2026.
- Kitada S., Andersen I., Akar S., Zapata J.M., Schiffer C.A., Takayama S., Krajewski S., WangH.-G., Zhang X., Bullrich E., Croce C.M., Rai K., Hines J., Reed J.C.
- Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia -.correlations with in viand in vivo chemoresponses. Blood, 1998, V. 91, p. 3379−3389.
- Kitada Sh., Zapata J.M., AndreefFM., Reed J.C.
- Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Brit. j. of Haematol., 1999, 106, p.995−1004.
- Kowal M., Kowal M., Dmoszynka A., Jawniak D., Lewandowski K., Wegrzyn J., Wolowiec D., Piszcz J., Roznowski K.
- Efficiency and toxicity of the fludarabine and cyclophosphamide comined therapy in relapsed/resistantpatients with B-cell chronic lymphocytic leukaemia-polish multicenter stady. The Hematology Journal, 2002, V. 3, S. l, p. 246.
- Kuribayashi N., Hata H., Yoshida M., Sonoki Т., Nagasaki A., Kimura Т., HaradaN., Matsuzaki H.
- Establishment and Characterization of a CD95(Fas/Apo-l)-Negative Myeloma Cell Line. Acta Haematol. 1999,101, p. 113−118.
- The Hematology Journal, 2002, V. 3, S. l, p. 248.
- Lazo-Langer A., Lome-MaldonadoC., Piedras J., Gaulard Ph., Quintanilla-Martinez L., Lopez-Karpovitch X.
- Fludarabine/Rituximab-Induced Cytogenetic Remission in a Patient with B-Cell Prolympho-cytic Leukemia Bearing Burkitt’s Variant Translocation t (2−8) (pl2-q24.1). Blood, 2002, V.100, Nol 1, part 2, p. 364b.
- LemoineN., Neoptolemos J., Cooke T. Cancer: a molecular approach. Oxford: Blakwell Scientific Publications, 1994.
- Leporrier M., Chevret S., Cazin B.
- Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage В and С chronic lymphocytic leukemia patients. Blood, 2001, Vol. 98, P. 2319−2325.
- Li X., Gong J., Feldman E.
- Apoptotic cell death during treatment of leukemias. Leuk. Lymphoma, 1994, V. 13, p. 65−70.
- Locke V.L., Davey R.A., Davey M.W.
- Altered drug sensitivity in response to idarubicin treatment in K562 human leukaemia cells. Brit. j. of Haematol., 1999, 106, p. 86−91
- Mahe В., Gueglio В., Morineau N., Vigier M., Moreau Ph., Chevallier P., Milpied N.J., Harousseau J.-L.
- Campath-l-H Therapy of Patients with Advanced B-Cell Chronic Lymphocytic Leukaemia. Blood, 2002, V.100, Nol 1, part 2, p. 361b.
- Mahmoodzadeh A., Pourfathollah A.
- The study of synergistic effect of gamma interferon and adriamycin on the human ery-throleukemia cell line К 562 clonogenic cells. The Hematol. Journal., 2003, V.4, S.2, p. 34.
- Manshouri Т., Keating M.I., Giles F., O’Brien S., Kantaijian H. M, Albitar M. Measuring Free Campath-IH and Correlaton with Circulating sCD52 and Total Campath. Blood, 2002, V.100, Noll, part 2, p. 361b.
- Manshouri Т., Keating M.J., Giles F., O’Brien S., Kantaijian H.M., Albitar M. Measuring Campath-1H Validation of a Sensitive and Simple Enzyme-Linked Immunosorbant Assay.
- Blood, 2002, V.100, Nol 1, part 2, p. 360b.
- Marce S., Ferrer A., Villaamor N., Bellosillo B.
- Drug induced apoptosis in cell from mantle cell lymphoma patients. The Hematol. Journal, 2003, V.4, S.2, p. 44.
- Marie J.-P., Legrand O., Simonin G., Zittoun R.
- Biological significance of «resistance» genes expression in acute leukemia. British Journal of Haematol., 1998, V.102,No l, p.5.
- Mason J.M., Drummond M.F., Bosanquet A.G., Sheldon T.A.
- DiSC assay: a cost-effective guide to treatment for chronic lymphocytic leukaemia? Intern, j. of Technology Assessment in Health Care, 1999, V. 15, p. 173−184.
- McConkey D.J., Chairdra J., Wright S.
- Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonu-clease cintent and relative expression of Bcl-2 and Bax. J. Immunol.- 1996.-V.156, № 7, p 2624−2629.
- McGanonAJ., Costa Pereira A.P., Daly L., Cotter T.G.
- Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system Brit. j. Of Haematol., 1998, 101, p.539−547.
- McKenna S.L., Padua R.A. Multidrug resistance in leukaemia.
- Brit. j. Of Haematology, 1997, V. 96, p. 659−674.
- McKenna S.L., Whittaker J.A., Padua R.A., Holmes J.A.
- Topoisomerase II expression in normal hemopoietic cells and chronic lymphocytic leukemia: drug sensitivity or resistance? Leukemia, 1993, V. 7, p. 1199−1203.
- Michieli M., Damiani D., ErmacoraA., Masolini P., Michelutti A., Michelutti Т., Russo D., Pea F., Baccarani M.1.posome-encapsulated daunorubicin for PGP-related multidrug resistance. Brit.j. of Haematol., 1999, 106, p. 92−99.
- Molica S., Vitelli G., Levato D., Gandolfo G., Liso V.1.creased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Brit.j. of Haematol., 1999, 107, p. 605−610.
- Montillo M., Cafro A.M., Tedeschi A., Brando В., Oreste P.G., Veronese S., Cairoli R., Pungolino E., Morra E.
- Consolidation with campath-lH in chronic lymphocytic leukemia responding to fludarabine is safe and effective.
- The Hematology Journal, 2002, V. 3, S. l, p. 248.129. Montserrat E., Rozman C.
- Current approaches to the treatment and management of chronic lymphocytic leukaemia. Drugs, 1994, Vol. 47, Suppl. 6, p. 1−9.
- Morabito F., Stelitano C., Callea I., Datolla A., Console G., Pucci G., Lacopino P., Cal-lea V., di RaimondoF., Brugiatelli M.1. vitro drug-induced cytotoxicity predicts clinical response to fludarabine in B-cell chroniclymphocytic leukaemia.
- Brit.j. of Haematol., 1998, 102, p. 528−531.
- Rapid colorimetric assay for cellular growth and survival. Application to prolifiration and cytotoxicity assays. J. Immunol. Methods, 1983, V.65, p. 55.
- Mulligan S.P., Wilson P.K., Christopherson R.I.
- Metabolic Response Patterns of Nucleotides in B-Cell Chronic Lymphocytic Leukaemia with Fludarabine, Cladribine and Deoxycoformycin. Blood, 2002, V.100, Nol 1, part 2, p. 362b.
- Nakazato Т., ItoK., Miyakawa Y., Ikeda Y., Kizaki M.
- A Green Tea component, catechin, rapidly induces apoptosis of myeloma cell via/+novel mitochondrial pathway triggered by the production of RoS. The hematol. Journ., 2003, V.4, S.2, p. 45.
- Norgaard J. M., Bukh A., Langkjer S. Т., Clausen N., Palshof Т., Hokland P. MDR-1 gene expression and drug resistance of AML cells.
- Brit. j. of Haematol., 1998, 100, p.534−540.
- O’Brian S., Kantaryian H., Estey E.1.ck of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N. Engl.j. Med., 1994, V. 330, p.319−22.
- O’Brien S., del Giglio A., Keating M.
- Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood-1995.- V.85, № 2.- p.307−318.
- O’Brien S.M., Kantarjian H.M., Cortes J., Beran M., Roller Ch.A., Giles F.J., Lerner S., Keating M.
- Results of the Fludarabine and Cyclophosphamide Combination Regimen in Chronic Lymphocytic Leukemia.
- Journal of Clin. Oncology, V.19,I5, 2001, 1414−1420.
- Orchard J., Ibbotson R., Davis Z., Stevenson F.K., Oscier D.G.
- CD38 expression and I-GV Gene Mutations are independent prognostic factors in chronic lymphicytic leukemia (CLL) and can be used to select stage a patient for treatment. Brit. j. Haematol., 2001. 113, S. 1, p.62.
- British Journal of Haematol., 1998, V.102,No l, p. l91.142. Oscier D.
- Chronic lymphocytic leukaemia.
- British Journal ofHaematology, 1999, V. 105, S. 1, p.1−3.
- Oscier D.G., Gardiner A.C., Mould S., Glide S., Davis Z., Ibbotson R.E., Corcoran M.M., Chapman R.M., Thomas P., Copplestoun J.A., Orchard J., Hablin T.J.
- Clinical stage, IGVH gene mutational status and loss or mutation of the P53 gene are independent prognostic factors in CLL. The Hematology Journal, 2002, V. 3, S. l, p. 357.
- Osipova E., Astrelina T.A., Roumiantsev S.A., Vladimieskaya E.B. MTT- test in prognosis of disease -free survival on ALL (3 yeas in observation) The Hematol. Journal 2003, V.4, S.2, p.36
- Otsuki Т., Yamada O., Sakaguchi H., Tomokuni A., Wada H., Yawata Y., UekiA. Human myeloma cell apoptosis inuced by interferon-a.
- Brit. j. Of Haematology, 1998, 103, p. 518−529.
- Pallis M., Tzanaki J., Harrison G., Weatley KL, Langabeer S., Burnett A. KL, Russell N.H.
- Association between reproducibl flow cytometric methodology for measuring multidrug resistance and remission rates in AML. British Journal of Haematol., 1998, V.102,No l, p.331.
- Panasci L., Paiement J.-P., Christodoulopoulos G., Belenkov A., Malapetsa A., Aloyz R. Chlorambucil Drug Resistance in chronic lymphocytic leukemia: The Emerging Role of DNA Repair.
- Clinical Cancer Res., 2001, V. 7, p. 454−461.
- Park C. J. Kin M. J. Seo E. J., etal.
- Vitro chemo sensitivity in acute leukemia. The Hematol. Journal 2003, V.4, S.2, p. 37.
- Paul J.Т., Johnston J.B., Neufeld N.J., KroppD.M., Ни X., Gibson S.B. Myeloid Cell Factor (Mcl-1) Expression and Drug Sensitivity in Chronic Lymphocytic Leukemia
- Blood, 2002, V. 100, No 11, part 2, p. 354b.
- Pepper C.J., Thomas A., Hoy Т., Fegan C., Bentley P.
- The vitamin D3 analogue, EB 1089, defines a novel class of therapeutic agents for the treatment of B-cell chronic lymphocytic leukemia. The Hematol. Journal 2003, V4, S2, p. 133
- Pepper CH., Hoy Т., Bentley P.
- Early up-regulation of BAX is a pre-requisite for chlorambucil-induced cell death in B-CLL. British j. OfHeamatol., V. 101, S. l, 1998, p.40.
- Pepper Ch., Thomas A., Hoy Т., Bentley P.
- Antisense-mediated reduction in BCL-2 expression is associated with increased in vitro apoptosis in b-cell chronic lymphocytic leukaemia. British Journal of Haematology, 1999, V. 105, S. 1, p. 84.
- Pepper Ch., Thomas A., Hoy Т., Cotter F., Bentley P.
- Antisense mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in Bcell chronic lymphocytic leukaemia.
- Brit. j. of Haematol., 1999, 107, p. 611−615.
- Pettitt A.R., Griffiths S.D., Cawley J.C.
- Spontaneous apoptosis in chronic lymphocytic leukaemia (CLL) is inhibited by homotypic cell-cell contact involving a sialic acidcontaining ligand. British j. OfHeamatol., V. 101, S. l, 1998, p.41.
- Pettitt A.R., Sherrington P.D., Cawley J.C.
- The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia. Brit. j. of Haematol., 1999, 106, p 1049−1051
- Pieters R., Huismans D.R., Loonen A.H., Hahlen K.
- Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukemia.1.ncet, 1991, V. 338(8764), p. 399−403.
- Pieters R., Huismans D.R., Loonen A.H., Hahlen K., van der Does-van den Berg A., van Wering E.R., Veerman A.J.P.
- Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. The Lancet, V.338,1991,p.399−403.
- Pieters R., Huismens D.R., Leyva A., VeermanA.J.
- Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. Cancer lett, 41(3), P323−323, 1988.
- Pieters R., Kaspers G.J.L., Klumper E., Veerman A.J.P.
- Clinical Relevance of In Vitro Drug Resistance Testing in Childhood Acute Lymphoblastic1. ukemia: The State of the Art.
- Medical and Pediatric Oncology 1994, 22, p. 299−308.
- Pieters R., Klumper E., Kaspers G.I.
- Drug resistance in childhood relapsed acute lymphoblastic leukemia. Proc. Annu Meet. Am. Soc. Clin. Oncol., 1992, V. 33, p. A1404.
- Pieters R., Loonen A.H., HuimansP.R., Broekema G.J.1. vitro drug sensitivity of cells from childrenwith leukemia using the MTT assay with im-pruved culture conditions Blood, 1990, V. 76, p.2327−2336.
- Blood, 2002, V.100, Noll, part 2, p. 353b.
- Potmesil M., Hsiang Y.H., Liu L.F., Bank В., Grossberg H., Kirschenbaum S., Forlenzar T.J., Penziner A., Kanganis D., Knowles D., Traganos F., Silber R.
- Resistance human leukemic and normal lymphocytes to drug-induced DNA cleavage and lowlevels of Dna topoisomerase II.
- Cancer Research, 1988, V. 48, p. 3537−3543.
- Pritsch O., Troussard X., Magnac Ch., Mauro F.R., Davi F., Payelle-Brogard В., Dumas G., Pulik M., Clerget F., Mandelli F., ChiorazziN., Schroeder H.W., Leporrier M., Dighiero G.
- Vh gene usage by family members affected with chronic lymphocytic leukaemia. Brit. j. of Haematol., 1999, 107, p. 616−624.
- Qiao Z., Wang H., Ren W., Zhu L., Zhang L.
- Tartaiy Buckwheat Flavonoid Induces Apoptosis in Human Leukemia Cell Lines. Blood, 2002, V.100, Nol 1, part 2, p. 215b.
- Rafel M., Colomer D., Bosch F., Bellosillo В., Cobo F., Villamor N., Montserrat E. In vitro cytotoxicity of purine analogues in B-cell chronic lymphocytic leukaemia. British Journal of Haematol., 1998, V.102,No l, p.330.
- Rai K.R., Peterson B.L., Appelbaum F.R. N. Engl. J. Med., 2000, N. 343, p. 1750−1757.
- Rai K.R., Sawitsky A., Cronkite Е.Р., Chanana A.D., Levy R.N. Clinical staging of chronic lymphocytic leukemia.
- Blood, 1975, V. 46, p. 219−234.170. Reed J.C.
- Molecular biology of chronic lymphocytic leukemia: implicftions for therapy Seminars in Hematol., 1998, V. 35, p. 3−13.
- Robac Т., Blonski J.Z., Kasznicki M., Gora-Tybor J., Dwilewicz-Trojaczek J., Stella-Holowiecka В., Wolowiec D.
- Cladribine combined with cyclophosphamide is highly effective in the treatment of the chronic lymphocytic leukemia.
- The Hematology Journal, 2002, V. 3, S. l, p. 247.
- Robac Т., Blonski J.Z., Kasznicki M., Gora-Tybor J., Hellmann A., Konopka L., Dmoszynska A., Dwilewicz-Trojaczek J., Wolowiec D.
- Re-treatment with cladribine-based regimens in relapsed B-CLL chronic lymphocytic leukemia.
- The Hematology Journal, 2002, V. 3, S. l, p. 246.173. Robak T.
- Cladribine in the treatment of chronic lymphocytic leukemia. Leuk. Lymphoma, 2001, 40(5−6), p.551−564.
- Cladribine with prednisone versus chlorambucil with prednisone as fierst-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood, 2000, V.96, No8, p.2723−2729.
- Rolinski J., Sieklucka M., Dmoszynska A., Wasik-Szczepanek E., Kowal M. Assessment of Ex Vivo. Spontaneous and Post Chemotherapeutic Apoptosis in Peripheral Blood Patients with B-CLL.
- Blood, 2002, V.100,Noll, part 2, p. 361B176. Roninson I.
- Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. New York, 1991, p. 406.
- Rossini F., Capalbo S., Fumagalli M., Battista C., De Santis G., Bolis S., Montesano R., Liso V., Pogliani E.M.
- Standart dose" — rituximab in refractory chronic lymphocytic leukemia The Hematology Journal, 2002, V. 3, S. l, p. 248.
- Saba H.I., Morelli G.A., Tannenum В., Loughran Th.P.
- Single-Center Experence of Campath® (alemtuzumab) Treatment of Refractory Chronic Lymphocytic Leukemia (CLL) Patients. Blood, 2002, V.100, Noll, part 2, p. 365b.179. SalmonS.E., Hersh E.M.
- Sensitivity of Multiple Myeloma to Imexon in the Human TumorCloning Assay. Joum. Of the National Cancer Institute, 1994, 86, 3, p, 229−230.
- Sargent J.M., Taylor C.G., Elgie A.W., Wilson K.K.
- The application of the MTT assaay to stady Drug resistance and dgug combination in acutelymphoblastic leukemia.
- Brit. j. Cancer, 1990, V. 62 (3), p. 512.
- Sarin A., Adams D.H., Henkart P.A. J. Exp. Med., 1993, V. 178, p. 1693−1701.
- Schmitt B.F., Franke., Burkhard O., Schlag R., Hopfinger G., Stauch M., Bergmann M., Wendtner C.M., Busch R., Emmerich В., Hallek M.
- Blood, 2002, V.100, Noll, part 2, p. 364b.
- Shi G.G., O’Brien S.M., Cortes J.E., Thomas D., Ker C., Beran M., Lerner S., Kantar-jian H.M., Keating M.J., Giles F.J.
- Amifostine (A) Does Not Decrease the Toxicity of the Fludarabine (F) Plus Cyclophosphamide^) Regimen. Blood, 2002, V.100, Noll, part 2, p. 366b.
- Silber R., Degar В., Costin D., Newcomb E.W., Mani M., Rosemberg C.R., Morse L., Drygas J.C., Canellakis Z.N., Potmesil M.
- Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood, 1994, V. 84, p. 3440−3446.186. Slater T.F., Sawyer B.
- Biochim. Biophis. Acta, 1963, V.77, p.383.
- Smolewski P., Cebula В., Robak Т., Johnson G.L., Lee B.W., Darzynkiewicz Z.
- Smolewski P., Szmigielska A., Cebula В., Rogalinska M. In vitro proapoptotic effect of alemtuzumab on B-CLL cells. The Hematol. Journ., 2003, V.4,S. 2, p.44.
- Solemani M., Pourfathollah, Moazzeni S., Arasteh.
- The combined effect of Gamma-interferon and chemotherapeutic drugs on KE-37 cell line. The Hematol. J., 2001, V. l, S. l, p. 80.190. Sonneveld P.
- How to circumvent clinical resistancein leukemia and lymphoma? British Journal of Haematol., 1998, V.102,No l, p.5.
- Spriano M., Chiurazzi F., Cassibba V., Leoni P., Liso V., Mazza P., Molica S., Bruni R., Clavio M., Gobbi M., Santini G.
- Multicentric prospectine randomised trial of fldarabine versus chlorambucil and prednisone in previously untreated patients with active B-chronic lymphocytic leukaemia (B-CLL): first interim report.
- British Journal of Haematol., 1998, V. 102, No 1, p. 191.
- Staib P., Dimski Т., Diehl V., Schinkothe T.
- Ambivalent modulation of ARA-CTP formation by fludarabine, gencitabine, 2-CDA and ben-damustin in AML.
- The Hematology Journal, 2002, V. 3, S. l, p. 313.
- Steinbach D., Furchtbar S., Sell W., Hermann J., Zintl F., Sauerbrey A.
- Contrary to Adult Patiens, Expression of the Multidrug Resistance Gene (MDR1) fails to Define a Poor Prognostic Group in Childhood AML. Blood, 2002, V.100, Nol 1, part 2, p. 215b.
- Stoetzer O.J., Podgrebniak A., Scholz M., Pelka-Fleischer R., Gullis E., Darsow M., Nussler V., Wilmanns W.
- Drug-induced apoptosis in chronic lymphocytic leukemia. Leukemia 1999, 13, p.1873−1880.
- Szmigielska-Kaplan, Robak Т.1.teractions of cladribine with antracyclines or mitoxantrone on murine leukemias L1210 and
- P 388 invivo and in vitro.
- The Hematol. J., 2001, V. l, S. l, p. 79.
- Tanghe A., Delforge A., Bernier M., Massey M., Bron D., Stryckmans R. Apoptosis of B-chronic limphocytic leukemia (CLL) cells in presence of glucocorticoids and modulation of their effect by interleukin-4.
- Drug Resistance in Leukemia and Lymphoma II edited by R. Pieters, G. J.L. Kaspers and A.J.P.Veerman, Netherlands, Harwood, 1997, p, 141−145.197. tasa Tasic J.T.
- High dose chlorambucil versus CHOP in patients with advanced B-chronic lymphocytic leukemia (B-CLL).
- The Hematology Journal, 2002, V. 3, S. l, p. 249.
- Thomas A., El Rouby S., Reed J.C., Krajewski S., Silber R., Potmesil M., Newcomb E.W.
- Drug induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax protein in drug resistance. Oncogene, 1996, V. 12, N. 5, p. 1055−1062.
- Tomoda A., Koshibu-Koizumi J., MizunoF., Takasaki M.
- A novel Phenoxazine, 2 Amino-4,4A-Dihydro-4A, 7Dimethyl-3H-Phenoxazine-3 jne, excerts anti-tumor activity against human B-cell and T-cell lymphoblastoid cell lines. The Hematol. j., 2003, V.4, S.2, p.91.
- Trafalis D.T., Camoutsis Ch., Pangalis G. A., Poulakidas E.1.stestronyl: a lastam steroidal ester of chlorambucil on the treatment of lymphocytic leukemia.
- The Hematol. Journal 2003 V.4, S.2, p.40.
- Trauth B.C., Klas C., Peters A.M.J. Science, 1989, V. 245, p. 301−305.
- Tsubata Т., Wu J., Honjo T. Nature, 1993, V. 364, p. 645−648.
- Twentyman P.R. Modulation of drug resistance.
- Drug Resistance in Leukemia and Limphoma II edited by R. Pieters, G. J.L. Kaspers and AJ.P.Veerman, Netherlands, Harwood, 1997, p, 403−411.
- Twentyman P.R., Fox N.E., Rees J.K.
- Alternative antracycines and resistance modifiers in human leukemias an in vitro stady using the MTT-assay
- Br.j.haematol:71(l)-P 19−24, 1989.
- Twentyman P.R., Fox N.E., Rees J.K.
- Chemosensitivity testing of fresh leukaemia cells using the MTT colorimetric assay. Brit. j. Haematol., 1989, V. 71(1), p. 19−24.
- Veerman A.J.P., Pieters R. ^ Drug sensitivity assays in leukemia and lymphoma.
- Br. j. Haematol., 1990, V.74, p. 381−384.
- Vorontsova E.V., Grishanova A.Y., Muchin O.V., Domnikova N.P., Lyakhovich V.V. Expression of MDR-associated cenes in bone marrow of patients with lymphoproliferative disease.
- The Hematology Journal, 2002, V. 3, S. l, p. 310.
- Wasik-Szczepanek E., Koczkodaj D., Dmoszynska A., Wach M. P53 mutations in patients with B-cell chronic lymphocytic leukemia. The Hematology Journal, 2002, V. 3, S. l, p. 244.
- Weisental L.M., Dill P. L, Finklestein J.Z.1.boratory detection of primary and aequired drug resistance in human lymphatic neoplasms. Cancer Treatment Reports 70:1283−1295, 1986.
- Weisenthal L.M., Dill P.L., Finklestein J.Z.1.boratory detection of primary and acquired drug resistance in human lymphatic neoplasms. Cancer Treatment Reports, 1986, V. 70, p. 1283−1295.
- Blood, 2002, V.100, Noll, part 2, p. 365b.
- Williams J.F., Petrus M.J., Wright J.A. Husebekk A., Fellowes V., Read E.J., Gress R.E., Fowler D.
- Fas-mediated lysis of chronic lymphocytic leukaemia cells: role of type I versus type II cytokines and autologous FasL-expressing T cells. Brit. j. of Haematol., 1999, 107, p. 99−105.
- Won J.H., Cheong H.J., Kim S. IC
- Erytroid differentiation and apoptosis of k562 cell resistant to ATTRA is induced by arsenic trioxide.
- The Hematol. Journ., 2003, V.4, S. 2, p. 44.
- Zaker F., Bakhshayesh M., Osati F.
- Anti tumoral and differentiation of Harmine and Harmaline on HL 60 treated with ATRA and G-CSF.
- The Hematol. Journal 2003 V.4, S.2, p. 35
- Zent C.S., Chen J.B., Kauscal G.P., Liu L., Schichman S.A. Caspase Activation by Clorambucil in Blood.
- Blood, 2002, V.100, Noll, part 2, p. 355b.
- Zhou P., Qian L.P., Bieszczad C. KL, Noelle ., Binder M., LevyN.B., Craing R.W. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage.
- Blood, 1998, V. 92, p.3226−3239.
- Kravtsov D., Greer J.P., Whitlock J.A., Koury M.J.
- Use of the microculture kinetic assay of apoptosis to determine chemosensitivities of leukemias.
- Blood, 1998, V. 92, p.968−980.
- Ormerod M.G., Orr R.M., Peacock J.H.
- The role of apoptosis in cell killing by cisplatinA a flow cytometry stady/ British J. Cancer, 1993, V.69, p.104−110.